Literature DB >> 15655705

Circulation and degradation of GIP and GLP-1.

C F Deacon1.   

Abstract

The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted from the intestinal K- and L-cells, respectively, but are immediately subject to rapid degradation. GLP-1 is found in two active forms, amidated GLP-1 (7-36) amide and glycine-extended GLP-1 (7-37), while GIP exists as a single 42 amino acid peptide. The aminopeptidase, dipeptidyl peptidase IV (DPP IV), which is found in the endothelium of the local capillary bed within the intestinal wall, is important for the initial inactivation of both peptides, with GLP-1 being particularly readily degraded. DPP IV cleavage generates N-terminally truncated metabolites (GLP-1 (9-36) amide / (9-37) and GIP (3-42)), which are the major circulating forms. Subsequently, the peptides may be degraded by other enzymes and extracted in an organ-specific manner. However, other endogenous metabolites have not yet been identified, possibly because existing assays are unable either to recognize them or to differentiate them from the primary metabolites. Neutral endopeptidase 24.11 has been demonstrated to be able to degrade GLP-1 in vivo, but its relevance in GIP metabolism has not yet been established. Intact GLP-1 and GIP are inactivated during passage across the hepatic bed by DPP IV associated with the hepatocytes, and further degraded by the peripheral tissues, while the kidney is important for the final elimination of the metabolites.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15655705     DOI: 10.1055/s-2004-826160

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  77 in total

1.  The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas.

Authors:  J de Heer; J Pedersen; C Orskov; J J Holst
Journal:  Diabetologia       Date:  2007-08-04       Impact factor: 10.122

2.  Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

Authors:  N Irwin; P L McClean; F P M O'Harte; V A Gault; P Harriott; P R Flatt
Journal:  Diabetologia       Date:  2007-05-08       Impact factor: 10.122

3.  Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study.

Authors:  L D Carbone; P Bůžková; H A Fink; J A Robbins; M Bethel; C M Isales; W D Hill
Journal:  Osteoporos Int       Date:  2017-02-02       Impact factor: 4.507

4.  Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury.

Authors:  Elliot J Glotfelty; Thomas Delgado; Luis B Tovar-Y-Romo; Yu Luo; Barry Hoffer; Lars Olson; Tobias Karlsson; Mark P Mattson; Brandon Harvey; David Tweedie; Yazhou Li; Nigel H Greig
Journal:  ACS Pharmacol Transl Sci       Date:  2019-02-11

5.  Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

Authors:  David A D'Alessio; Amanda M Denney; Linda M Hermiller; Ronald L Prigeon; Julie M Martin; William G Tharp; Monica Liqueros Saylan; Yanling He; Beth E Dunning; James E Foley; Richard E Pratley
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

6.  Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis.

Authors:  Eva Tomas; Joel F Habener
Journal:  Trends Endocrinol Metab       Date:  2009-12-16       Impact factor: 12.015

7.  The role of incretins in cardiovascular control.

Authors:  Derek D Mafong; Robert R Henry
Journal:  Curr Hypertens Rep       Date:  2009-02       Impact factor: 5.369

Review 8.  The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review.

Authors:  Jonathan D Newman; Anish K Vani; Jose O Aleman; Howard S Weintraub; Jeffrey S Berger; Arthur Z Schwartzbard
Journal:  J Am Coll Cardiol       Date:  2018-10-09       Impact factor: 24.094

Review 9.  Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence?

Authors:  Mousumi Bose; Blanca Oliván; Julio Teixeira; F Xavier Pi-Sunyer; Blandine Laferrère
Journal:  Obes Surg       Date:  2008-09-27       Impact factor: 4.129

Review 10.  A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.

Authors:  Enrique Z Fisman; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2009-07-20       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.